Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Small cap and Mid cap in favour
Wed, 19 Jun 01:30 pm

Indian equity markets continued to trade weak during the post noon trading session. Barring stocks from the metal, consumer durables and realty sectors; all the sectoral indices are trading in the red. Among the pack of losers, stocks from the IT and power sectors are witnessing maximum selling pressure.

BSE-Sensex is down by 66 points and NSE-Nifty is trading down by 18 points. While BSE Mid Cap is trading up by 0.42%, BSE Small Cap index is trading up by 0.27%. The rupee is trading at 58.72 to the US dollar.

Majority of the large IT companies are trading in the green with Moser Baer and Mahindra Satyam being the biggest gainers. As per a leading financial daily, Tata Consultancy Services (TCS) has announced that it will join US2020 as a founding leadership partner. US2020 is a National Education initiative that has a target to provide 1 m science, technology, engineering and math (STEM) professionals with mentorship opportunities by 2020. For this TCS will offer US$ 0.5 m monetary support. TCS will also develop online matching platform that will provide mentoring opportunities to STEM volunteers with top non-profit organizations. As per the strategy, five cities will be selected and given US$ 1 m in cash and kind support for bringing together businesses, non-profit organizations, city governments and local philanthropies to mobilize STEM volunteers. TCS is aspiring to get 20% of the company's STEM workforce mentoring students by 2020. TCS stock is trading down by 1%.

Indian pharma stocks are trading mixed with Dishman Pharma and Orchid Chemicals being among the major gainers while Dr Reddy's and Natco Pharma are the leading losers. Glenmark Pharma's subsidiary, Glenmark Generics Inc USA, has announced the approval of Riluzole tablets 50 mg from the United States Food and Drug Administration (USFDA). The company has already commenced the shipping of the drugs. The said drug is indicated for the treatment of amyotrophic lateral sclerosis. The branded sales of Riluzole as on March 2013 were US$ 64 m in the US. Glenmark was trading up by 0.7%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Small cap and Mid cap in favour". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.